Skip to main content
Erschienen in: European Journal of Pediatrics 12/2021

06.06.2021 | Original Article

Renal manifestations in children with neurofibromatosis type 1

verfasst von: Binnaz Celik, Ozlem Yuksel Aksoy, Funda Bastug, Hatice Gamze Poyrazoglu

Erschienen in: European Journal of Pediatrics | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal-dominant neurocutaneous syndrome affecting various parts of the body, including the renovascular and urinary systems. We evaluated the renovascular, urinary, glomerular, and tubular functions of children with NF1. We compared blood pressures, urinary findings, and renal glomerular and tubular functions in children with NF1 with those of a healthy age- and gender-matched control group. We evaluated 46 NF1 patients and 33 healthy controls. The mean ages of the NF1 group (female/male: 20/26) and the control group (female/male: 15/18) were 10.1 ± 4.6 and 10.6 ± 4.3 years respectively. Six NF1 patients were hypertensive. The mean blood pressures of the NF1 group were significantly higher than those of the control group. Renal artery stenosis was detected in one NF1 patient. Urinary tract anomalies were evident in 21.7% of NF1 but only 9% of control subjects. The mean estimated glomerular filtration rate (eGFR) of the NF1 group was significantly lower than that of the control group. Six NF1 patients evidenced eGFRs < 90 mL/min. In the NF1 group, tubular phosphorus reabsorption was significantly lower and uric acid excretion significantly higher than in the control group.
Conclusion: Hypertension, urinary tract anomalies, and impaired renal function were more common in NF1 patients than healthy controls. Regular blood pressure measurements and evaluation of urinary tract and kidney function are essential for NF1 patients.
What is Known:
• NF1 is most commonly associated with systemic hypertension due to renal artery vasculopathy and the development of a pheochromocytoma.
• Hydronephrosis and bladder involvement have been documented in NF1.
What is New:
• Renal glomerular and tubular functions may be affected in NF1.
Literatur
2.
Zurück zum Zitat Weiss B, Bollag G, Shannon K (1999) Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14–22CrossRef Weiss B, Bollag G, Shannon K (1999) Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am J Med Genet 89:14–22CrossRef
4.
Zurück zum Zitat Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, Mcmanus B, Korf BR (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascuar task force. Genet Med 4:105–111CrossRef Friedman JM, Arbiser J, Epstein JA, Gutmann DH, Huot SJ, Lin AE, Mcmanus B, Korf BR (2002) Cardiovascular disease in neurofibromatosis 1: report of the NF1 cardiovascuar task force. Genet Med 4:105–111CrossRef
5.
Zurück zum Zitat Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D, Macedo TA, Stanson A (2007) Vascular abnormalities in patients with neurofibromatosis syndrome type 1: clinical spectrum, management and results. J Vasc Surg 46:475–484CrossRef Oderich GS, Sullivan TM, Bower TC, Gloviczki P, Miller DV, Babovic-Vuksanovic D, Macedo TA, Stanson A (2007) Vascular abnormalities in patients with neurofibromatosis syndrome type 1: clinical spectrum, management and results. J Vasc Surg 46:475–484CrossRef
6.
Zurück zum Zitat Norton KK, Xu J, Guttman DH (1995) Expression of the neurofibromatosis 1 gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21CrossRef Norton KK, Xu J, Guttman DH (1995) Expression of the neurofibromatosis 1 gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21CrossRef
7.
Zurück zum Zitat Jouhilahti EM, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178:1932–1939CrossRef Jouhilahti EM, Peltonen S, Heape AM, Peltonen J (2011) The pathoetiology of neurofibromatosis 1. Am J Pathol 178:1932–1939CrossRef
8.
Zurück zum Zitat Pycha A, Klingler CH, Reiter WJ, Schroth B, Haitel A, Latal D (2001) Von Recklinghausen neurofibromatosis with urinary bladder involvement. Urology 58:106CrossRef Pycha A, Klingler CH, Reiter WJ, Schroth B, Haitel A, Latal D (2001) Von Recklinghausen neurofibromatosis with urinary bladder involvement. Urology 58:106CrossRef
9.
Zurück zum Zitat Kaefer M, Adams MC, Rink RC, Keating MA (1997) Principles in management of complex pediatric genitourinary plexiform neurofibroma. Urology 49:936–940CrossRef Kaefer M, Adams MC, Rink RC, Keating MA (1997) Principles in management of complex pediatric genitourinary plexiform neurofibroma. Urology 49:936–940CrossRef
10.
Zurück zum Zitat Kaas B, Huisman TA, Tekes A et al (2013) Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol 28:561–569CrossRef Kaas B, Huisman TA, Tekes A et al (2013) Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. J Child Neurol 28:561–569CrossRef
13.
Zurück zum Zitat Tóth T, Trinn C, Simon L, Nagy J (1996) A case of membranous glomerulonephritis associated with Recklinghausen’s neurofibromatosis. Clin Nephrol 45:271–272PubMed Tóth T, Trinn C, Simon L, Nagy J (1996) A case of membranous glomerulonephritis associated with Recklinghausen’s neurofibromatosis. Clin Nephrol 45:271–272PubMed
14.
Zurück zum Zitat Wani MM, Reshi AR, Banday KA, Najar MS (2006) von Recklinghausen’s neurofibromatosis associated with membranous glomerulonephritis. Saudi Med J 27:534–535PubMed Wani MM, Reshi AR, Banday KA, Najar MS (2006) von Recklinghausen’s neurofibromatosis associated with membranous glomerulonephritis. Saudi Med J 27:534–535PubMed
15.
Zurück zum Zitat Taniguchi Y, Yorioka N, Kanbe M, Okushin S, Oda H, Nishida Y, Kushihata S&;, Murakami I, Yamakido M (1997) Parent and child cases of IgA nephropathy associated with von Recklinghausen’s disease. Nephron 75:113–114. https://doi.org/10.1159/000189515 Taniguchi Y, Yorioka N, Kanbe M, Okushin S, Oda H, Nishida Y, Kushihata S&;, Murakami I, Yamakido M (1997) Parent and child cases of IgA nephropathy associated with von Recklinghausen’s disease. Nephron 75:113–114. https://​doi.​org/​10.​1159/​000189515
17.
Zurück zum Zitat Tarrass F (2008) Focal and segmental glomerulosclerosis and von Recklinghausen’s neurofibromatosis: coincidental or associated? Saudi J Kidney Dis Transpl 19:453–454PubMed Tarrass F (2008) Focal and segmental glomerulosclerosis and von Recklinghausen’s neurofibromatosis: coincidental or associated? Saudi J Kidney Dis Transpl 19:453–454PubMed
19.
Zurück zum Zitat Orera A, Lacarra S, Fernández L, Gómez N, Slon MF, Manrique J (2019) Síndrome nefrótico secundario en neurofibromatosis tipo 1. A propósito de dos casos [Secondary glomerulonephritis in neurofibromatosis type 1. Two case reports]. An Sist Sanit Navar 42:345–349. https://doi.org/10.23938/ASSN.0720CrossRefPubMed Orera A, Lacarra S, Fernández L, Gómez N, Slon MF, Manrique J (2019) Síndrome nefrótico secundario en neurofibromatosis tipo 1. A propósito de dos casos [Secondary glomerulonephritis in neurofibromatosis type 1. Two case reports]. An Sist Sanit Navar 42:345–349. https://​doi.​org/​10.​23938/​ASSN.​0720CrossRefPubMed
22.
Zurück zum Zitat DeBella K, Szudek J, Friedman JM (2000) Use of the national institutes of health criteria for diagnosis of neurofibromatosis1 in children. Pediatrics 105:608–614CrossRef DeBella K, Szudek J, Friedman JM (2000) Use of the national institutes of health criteria for diagnosis of neurofibromatosis1 in children. Pediatrics 105:608–614CrossRef
23.
Zurück zum Zitat Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Subcommittee on screening and management of high blood pressure in children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 140:e20173035CrossRef Flynn JT, Kaelber DC, Baker-Smith CM et al (2017) Subcommittee on screening and management of high blood pressure in children. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 140:e20173035CrossRef
24.
Zurück zum Zitat Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMed
27.
Zurück zum Zitat Dubov T, Alhadef HT, Chernin G, Constantini S, Cleper R, Shachar SB (2016) High prevalence of elevated blood pressure among children with neurofibromatosis type 1. Pediatr Nephrol 31:131–136CrossRef Dubov T, Alhadef HT, Chernin G, Constantini S, Cleper R, Shachar SB (2016) High prevalence of elevated blood pressure among children with neurofibromatosis type 1. Pediatr Nephrol 31:131–136CrossRef
31.
Zurück zum Zitat Fossali E, Signorini E, İntermite RC et al (2000) Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 14:806–810CrossRef Fossali E, Signorini E, İntermite RC et al (2000) Renovascular disease and hypertension in children with neurofibromatosis. Pediatr Nephrol 14:806–810CrossRef
32.
Zurück zum Zitat Leppӓvirta J, Kallionpӓӓ RA, Uusitalo E et al (2018) Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study. Orphanet J Rare Dis 13:5CrossRef Leppӓvirta J, Kallionpӓӓ RA, Uusitalo E et al (2018) Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study. Orphanet J Rare Dis 13:5CrossRef
33.
Zurück zum Zitat Senel S, Erkek N, Karacan CD (2010) Neurofibromatosis type 1 with idiopathic hypercalciuria, nephrolithiasis and horshoe kidney. Pediatr Nephrol 25:1575–1576CrossRef Senel S, Erkek N, Karacan CD (2010) Neurofibromatosis type 1 with idiopathic hypercalciuria, nephrolithiasis and horshoe kidney. Pediatr Nephrol 25:1575–1576CrossRef
38.
Zurück zum Zitat Ali US (2011) Joubert syndrome with nephronophthisis in neurofibromatosis type 1. Saudi J Kidney Dis Transpl 22:788–791PubMed Ali US (2011) Joubert syndrome with nephronophthisis in neurofibromatosis type 1. Saudi J Kidney Dis Transpl 22:788–791PubMed
39.
43.
Zurück zum Zitat Nguyen KT, Chiu M (2008) Segmental neurofibromatosis associated with renal angiomyolipomas. Cutis 82:65–68PubMed Nguyen KT, Chiu M (2008) Segmental neurofibromatosis associated with renal angiomyolipomas. Cutis 82:65–68PubMed
44.
Zurück zum Zitat Iarrobino G, Capasso L, Buonincontro S, Alderisio A, Sciano D, Calabrese R, Borsi E (2008) Chirurgia conservativa del parenchima renale per angiomiolipoma emorragico: due casi clinici [Preservative surgery of the kidney for haemorrhagic angiomyolipoma: a report of two cases]. Chir Ital 60:587–593PubMed Iarrobino G, Capasso L, Buonincontro S, Alderisio A, Sciano D, Calabrese R, Borsi E (2008) Chirurgia conservativa del parenchima renale per angiomiolipoma emorragico: due casi clinici [Preservative surgery of the kidney for haemorrhagic angiomyolipoma: a report of two cases]. Chir Ital 60:587–593PubMed
Metadaten
Titel
Renal manifestations in children with neurofibromatosis type 1
verfasst von
Binnaz Celik
Ozlem Yuksel Aksoy
Funda Bastug
Hatice Gamze Poyrazoglu
Publikationsdatum
06.06.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Pediatrics / Ausgabe 12/2021
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-021-04144-6

Weitere Artikel der Ausgabe 12/2021

European Journal of Pediatrics 12/2021 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.